Trials / Conditions / Resectable Pancreatic Adenocarcinoma

Resectable Pancreatic Adenocarcinoma

17 registered clinical trials studyying Resectable Pancreatic Adenocarcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer NCT07080021	Ruijin Hospital	—
Recruiting	Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) i NCT06816914	Taichung Veterans General Hospital	Phase 2
Recruiting	Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) NCT06384560	Amsterdam UMC, location VUmc	Phase 1 / Phase 2
Recruiting	Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Bl NCT06649474	University Hospital, Clermont-Ferrand	N/A
Recruiting	Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline NCT06423326	Emory University	Phase 2
Unknown	Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer NCT06168552	Zhejiang University	Phase 1 / Phase 2
Recruiting	Identify microRNAs in Cachexia in Pancreatic Carcinoma NCT05275075	University of Oklahoma	—
Unknown	Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis NCT05754788	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—
Active Not Recruiting	Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borde NCT04940286	M.D. Anderson Cancer Center	Phase 2
Recruiting	Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer NCT04927780	Erasmus Medical Center	Phase 3
Unknown	Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma NCT04915417	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Recruiting	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy NCT04858334	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer NCT04340141	Alliance for Clinical Trials in Oncology	Phase 3
Unknown	A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma NCT05066802	Yonsei University	Phase 2
Completed	Intraoperative Radiation Therapy for Resectable Pancreatic Cancer NCT03273374	Gangnam Severance Hospital	N/A
Unknown	Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer NCT03251365	Hospital General de Ciudad Real	Phase 2 / Phase 3
Completed	Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma NCT00600002	Edward Nelson	Phase 1